TAICANG China April 24 2018 PRNewswire Connect Biopharmaceuticals Ltd. today announced that it has submitted an application in Australia to begin a phase 1 clinical trial to evaluate CBP201 the company's monoclonal antibody candidate for allergic inflamma...
↧